The present study was carried out to prepare and evaluate an inactivated vaccine from new isolate rabbit hemorrhagic disease (RHD) virus that causes outbreaks in rabbit flocks vaccinated with commercially available vaccines. Sixty, 3 months old New Zealand rabbits were allotted into four groups (A, B, C, D). Groups A, B, C were vaccinated subcutaneously with the new isolate of RHD virus vaccine, Izovac Mevax and SVRI vaccines respectively. Group D was kept as unvaccinated control. All rabbits were challenged at 10 days post vaccination by intranasal inoculation. Rabbits in all groups were observed daily for clinical signs and mortalities. Hemagglutination inhibition titers, hematological, biochemical and histopathological changes were studied throughout the experimental period. Immunological response and resistance to challenge were highest in group A which was vaccinated with the new isolate RHD virus vaccine, meanwhile rabbits in this group maintained a good general health status as reflected by biochemical and hematological pictures. According to these findings, the new isolate RHD virus vaccine is strongly recommended to minimize economic losses that RHD virus outbreaks can produce in industrial rabbitries.